Potassium Hydroxide → 1-(4-((1-(tert-Butoxycarbonyl)piperidin-3-yl)methylamino)-6-(5-cyanopyrazin-2-ylamino)pyridin-3-yl)-1H-pyrrole-3-carboxylic acid

HRID 556827ノート

反応式

HRID 556827 の反応式
[C:1]([C:3]1[N:4]=[CH:5][C:6]([NH:9][C:10]2[CH:15]=[C:14]([NH:16][CH2:17][CH:18]3[CH2:23][CH2:22][CH2:21][N:20]([C:24]([O:26][C:27]([CH3:30])([CH3:29])[CH3:28])=[O:25])[CH2:19]3)[C:13]([N:31]3[CH:35]=[CH:34][C:33]([C:36]([O:38]CC)=[O:37])=[CH:32]3)=[CH:12][N:11]=2)=[N:7][CH:8]=1)#[N:2].[OH-].[K+]>C(O)C>[C:27]([O:26][C:24]([N:20]1[CH2:21][CH2:22][CH2:23][CH:18]([CH2:17][NH:16][C:14]2[CH:15]=[C:10]([NH:9][C:6]3[CH:5]=[N:4][C:3]([C:1]#[N:2])=[CH:8][N:7]=3)[N:11]=[CH:12][C:13]=2[N:31]2[CH:35]=[CH:34][C:33]([C:36]([OH:38])=[O:37])=[CH:32]2)[CH2:19]1)=[O:25])([CH3:30])([CH3:28])[CH3:29]

参加物

4

反応物 2

HCID 14797Potassium HydroxideHCID 71022175tert-Butyl 3-((2-(5-cyanopyrazin-2-ylamino)-5-(3-(ethoxycarbonyl)-1H-pyrrol-1-yl)pyridin-4-ylamino)methyl)piperidine-1-carboxylate

生成物 1

HCID 667465061-(4-((1-(tert-Butoxycarbonyl)piperidin-3-yl)methylamino)-6-(5-cyanopyrazin-2-ylamino)pyridin-3-yl)-1H-pyrrole-3-carboxylic acid

試薬・触媒・溶媒 1

HCID 702Ethanol溶媒

反応条件

温度
50 °C

実験手順

tert-Butyl 3-((2-(5-cyanopyrazin-2-ylamino)-5-(3-(ethoxycarbonyl)-1H-pyrrol-1-yl)pyridin-4-ylamino)methyl)piperidine-1-carboxylate (42 mg, 0.077 mmol) was dissolved in ethanol (1 mL). KOH (43 mg, 0.770 mmol) was added and the solution was stirred at 50° C. for 72 h. The reaction mixture was evaporated to dryness and the residue was partitioned between water and dichloromethane. The two phases were separated and the organic phase was extracted with water. The combined aqueous phases were neutralised to pH 7 by the addition of 1M HCl and then evaporated to dryness. The product (7 mg, 17%) was used directly in the next step without further purification.

後処理

  1. customThe reaction mixture was evaporated to dryness
  2. customthe residue was partitioned between water and dichloromethane
  3. customThe two phases were separated
  4. extractionthe organic phase was extracted with water
  5. additionThe combined aqueous phases were neutralised to pH 7 by the addition of 1M HCl
  6. customevaporated to dryness
  7. customThe product (7 mg, 17%) was used directly in the next step without further purification

出典と根拠

ORDレコード
ord-ec5d720f22c041afab7b751147f98287
出典データセット
uspto-grants-2011_11
特許番号
US08058045B2

反応ノート

読み込み中…